1. France Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
OSE Immunotherapeutics SA

OSE Immunotherapeutics SA

2.07
EUR
-0.01
(-0.39%)
159.62MMarket Cap
Mar 31Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
0.03
0.47
1.67
1.74
0.67
1.45
0.99
0.11
3.2
0.12
- -
Basic EPS, GAAP
-0.03
-0.36
-0.59
1.65
-0.73
0.38
-0.31
-1.06
-0.93
-0.96
-1.18
1.72
-1.69
- -
Free Cash Flow per Basic Share
-0.03
-0.25
-0.49
0.05
-0.58
0.03
0.59
-1.27
-0.57
-1
-1.02
2.22
-1.53
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.11
-0.1
1.45
4.5
3.84
4.18
3.91
3.42
2.59
1.77
1.06
2.91
1.24
2.91
Tangible Book Value per Share
-0.11
-0.1
1.45
0.83
0.2
0.62
0.4
0.49
-0.17
-0.87
-1.09
0.9
-0.61
0.9
Basic Weighted Avg Shares
8
8
10
13
14
15
15
16
18
19
20
22
22
22
Sales/Revenue/Turnover
- -
- -
- -
- -
7
24
26
10
26
18
2
70
3
- -
Operating Margin (%)
- -
- -
-135,500
-2,757.44
-188.91
19.82
-5.67
-182.3
-63.2
-100.51
-1,035.07
62.35
-1,396.26
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
1
3
4
4
3
3
- -
Net Income, GAAP
- -
-3
-6
21
-11
5
-5
-17
-17
-18
-23
37
-38
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5.99
- -
- -
Profit Margin (%)
- -
- -
-139,600
5,395.82
-157.18
22.45
-17.93
-158.91
-64.05
-97.04
-1,032.91
53.59
-1,439.06
- -
Working Capital
- -
- -
15
18
9
14
19
26
27
21
12
50
7
50
LT Debt
1
1
- -
1
4
4
11
19
35
41
39
38
25
38
Total Equity
-1
-1
14
65
55
62
59
61
48
33
23
64
28
64
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
45.9
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
45.24
- -
- -
Return on Common Equity (%)
- -
- -
- -
52.32
-17.51
9.37
-7.73
-27.61
-30.85
-44.1
-82.7
86.29
-82.32
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
7
4
8
LT Borrowings
36
37
36
LT Finance Leases
3
3
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
22
22
22
Market Capitalization
93
129
160

Working Capital

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
30
86
70
Cash, Cash Equivalents & STI
19
76
59
Accounts Receivable, Net
1
5
4
Inventories
- -
- -
- -
Total Current Liabilities
19
17
20
Payables & Accruals
- -
- -
- -
ST Debt
7
4
8
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
38.05%
7.56%
-56.5%
Free Cash Flow
-67.67%
-94.74%
-170.26%
Net Income, GAAP
-112.88%
-85.35%
-200.65%
Sales/Revenue/Turnover
1,430.76%
595.14%
-96.25%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2
2024
- -
- -
70
2025
- -
- -
3

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-1.18
2024
- -
- -
1.72
2025
- -
- -
-1.69

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Marc Le Bozec
Full Time Employees
64
Sector
Health technology
Industry
Pharmaceuticals: major
Address
22, boulevard Benoni Goullin Nantes France 44200
IPO Date
Mar 30, 2015
Website
ose-immuno.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
OSE Immunotherapeutics SA (OSE.PA; ORPOF) is a clinical-stage biotechnology company focused on developing first-in-class immunotherapies targeting immune activation and regulation in immuno-oncology and immuno-inflammation. The company offers a diverse pipeline including Tedopi, a neoepitope-based cancer vaccine in Phase III for non-small cell lung cancer and Phase II for pancreatic and ovarian cancers; OSE-279 in Phase I/II for advanced solid tumors and lymphomas; OSE-127, a monoclonal antibody in Phase II for ulcerative colitis and Sjögren’s syndrome; FR104 in Phase I for rheumatoid arthritis; BI 765063 and BI 770371, anti-SIRPα antagonists licensed to Boehringer Ingelheim for solid tumors; OSE-703 and OSE-172 targeting myeloid suppressive cells in the tumor microenvironment; OSE-230, an agonist antibody against ChemR23 for chronic inflammation; CLEC-1 monoclonal antibody antagonists; and BiCKI, a bispecific PD-1 checkpoint inhibitor platform, alongside preclinical platforms in neoepitopes, cis-targeting anti-PD1/cytokines, and mRNA technologies under the HexARN program. Founded in 2012 and headquartered in Nantes, France, with operations in Paris, OSE Immunotherapeutics employs over 65 staff and maintains global partnerships serving pharmaceutical collaborators and clinical trial patients primarily in Europe and the United States. Recent developments include a 2024 strategic partnership with AbbVie potentially worth up to $713 million including a $48 million upfront payment for immunology assets; expansion of its Boehringer Ingelheim collaboration with a €25.3 million one-time payment for anti-SIRPα programs in immuno-oncology and cardiovascular-renal-metabolic diseases, plus a €13.5 million upfront asset acquisition for a cis-targeting anti-PD1/cytokine program; €8.4 million in non-dilutive France 2030 funding for Tedopi’s Phase III trial; and a May 2025 collaboration with Inside Therapeutics and MiNT Laboratory funded by €1.3 million for mRNA nanodrug advancement; alongside a September 2025 strategic partnership with Inserm Transfert and Nantes University.